Alzheimer’s Disease Mouse Models
Complimentary range of Alzheimer’s disease mouse models that recapitulate key neurodegenerative disease characteristics
As a European preclinical neurology contract research organization (CRO), InnoSer provides you with a portfolio of Alzheimer’s disease mouse models that are relevant for performing preclinical efficacy research studies. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs. InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
InnoSer offers multiple Alzheimer’s disease mouse models for preclinical research, including APP transgenic mice as well as transgenic Tau and Tau seeding mouse models using recombinant and/or patient-derived seeds. However, as each model is unique, modelling distinct pathophysiological aspects of Alzheimer’s disease, we recommend you discuss the most appropriate model with our neurology study directors.
Alzheimer’s Disease Mouse Model options
APP Transgenic Mice
InnoSer offers preclinical research services with several different transgenic amyloid models, which recapitulate the plaque pathology of AD.
Transgenic Tau Mouse Models
InnoSer offers unique research services with several different transgenic tau models, which recapitulate the Tau neurofibrillary tangle pathology of AD.
Tau Seeding Mouse Models
InnoSer uses an AD brain extract injection model, providing unique preclinical services with a translational model of Tau pathology seeding and spreading.
Rodent Behavioral Testing Made Simple.
Explore our extensive portfolio of validated and tailored behavioral and cognitive rodent tests designed to advance your research.
Alzheimer’s disease dementia
Pathology in the brain: amyloid and tau
These Aβ aggregates are believed to contribute, at least partially, to subsequent pathological processes such as tau misfolding, synaptic toxicity, and inflammation. The presence of tau pathology is closely associated with neurodegeneration and cognitive decline in AD. Researchers can recreate both pathologies by utilizing transgenic mice or through the introduction of viral vectors or aggregate-containing brain extracts from AD patients.
Transgenic P301S (PS19) mice show Tau pathology (AT8; phosphorylated Tau) at 8 months of age
Risk factors: APOE4
Mice with a humanized APOE4 gene serve as valuable models for evaluating APOE-targeting therapeutics. These APOE models are often crossed with amyloid or tauopathy mouse models, enhancing the observed phenotypes and further contributing to Alzheimer’s disease research.
The people behind the models
Jolien Beekens, PhD, Neurology Study Director
With in vitro screening methods available as a suited first step in your development process our team of experts have the experience to optimise your study design process.
Thomas Vogels, PhD, Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com